Last Gasp Or New Life? 2009's Novel Products Have Blockbuster Potential
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers a possible a return of the blockbuster.
You may also be interested in...
Chart: "Wild Cards: NMEs and New Biologics That Are Still Pending After FDA Missed User Fee Goal Dates In 2008"
Wild Cards: NMEs and New Biologics That Are Still Pending After FDA Missed User Fee Goal Dates In 2008
Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme
In 2009, some of the biggest new drugs might not technically be drugs at all. Major biologic products could dominate the upcoming year, largely thanks to big pharma's maturing interest in biotechnology
Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme
In 2009, some of the biggest new drugs might not technically be drugs at all. Major biologic products could dominate the upcoming year, largely thanks to big pharma's maturing interest in biotechnology